Sign In
Buy TRDA
$6.58
-0.0600 (-0.90%)
At Close: Jun 03, 2026
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
07:00am, Monday, 03'rd Jun 2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class
Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet
10:56am, Tuesday, 21'st May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 37.1% in Entrada Therapeutics (TRDA). While the effectiveness of this highly sought-after metric is questionabl
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
07:00am, Thursday, 16'th May 2024
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class o
Entrada Therapeutics Reports First Quarter 2024 Financial Results
07:00am, Tuesday, 07'th May 2024
– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 –
New Strong Sell Stocks for March 18th
10:15am, Monday, 18'th Mar 2024
ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
07:00am, Wednesday, 13'th Mar 2024
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort o
Entrada Therapeutics to Present at Upcoming Investor Conferences
07:00am, Wednesday, 07'th Feb 2024
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
07:40pm, Monday, 18'th Dec 2023
NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are ad
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
01:39pm, Wednesday, 29'th Nov 2023
NEW YORK , Nov. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advi
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug
01:31pm, Thursday, 23'rd Nov 2023
Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.
Entrada Therapeutics shares tumble as FDA refuses to lift hold on muscular dystrophy trial
11:52am, Wednesday, 22'nd Nov 2023
Entrada Therapeutics shares plummeted almost 30% after it announced that the U.S. Food and Drug Administration (FDA) has refused to lift its clinical hold on its Phase 1 study of its investigational
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
07:00am, Wednesday, 22'nd Nov 2023
– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in seco
Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates
09:46am, Tuesday, 07'th Nov 2023
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of a loss of $0.55 per share. This compares to loss of $0.80 per share a yea
Entrada Therapeutics to Present at Upcoming Investor Conferences
07:00am, Thursday, 12'th Oct 2023
BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular
– Initiation of Phase 1 clinical trial marks Entrada's transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada T
